Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primat...

Full description

Bibliographic Details
Main Authors: Jonathan G. Pol, Sergio A. Acuna, Beta Yadollahi, Nan Tang, Kyle B. Stephenson, Matthew J. Atherton, David Hanwell, Alexander El-Warrak, Alyssa Goldstein, Badru Moloo, Patricia V. Turner, Roberto Lopez, Sandra LaFrance, Carole Evelegh, Galina Denisova, Robin Parsons, Jamie Millar, Gautier Stoll, Chantal G. Martin, Julia Pomoransky, Caroline J. Breitbach, Jonathan L. Bramson, John C. Bell, Yonghong Wan, David F. Stojdl, Brian D. Lichty, J. Andrea McCart
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:OncoImmunology
Subjects:
oncolytic vaccination
mg1 maraba
mage-a3
cancer immunotherapy
endogenous immunity
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1512329

Internet

http://dx.doi.org/10.1080/2162402X.2018.1512329

Similar Items